{ "resourceType" : "Evidence", "id" : "293991", "meta" : { "versionId" : "9", "lastUpdated" : "2025-10-07T17:12:54.639Z", "profile" : ["http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"] }, "language" : "en", "text" : { "status" : "generated", "div" : "

Generated Narrative: Evidence 293991

version: 9; Last updated: 2025-10-07 17:12:54+0000; Language: en

Profile: InterventionOnlyEvidence

url: https://fevir.net/resources/Evidence/293991

identifier: FEvIR Object Identifier/293991, outcomeId/109588, picoId/85798, sectionId/73215

name: Body_weight_Intervention_Evidence_from_MAGICapp_109588

title: MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes

citeAs:

MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293991. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293991. Computable resource at: https://fevir.net/resources/Evidence/293991#json.

\n

status: Active

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication)InterventionOnlyEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

\n

RelatesTos

-TypeTarget[x]
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

\n

variableDefinition

description:

Adults with type 2 diabetes -- SGLT2 inhibitors

\n

variableRole: Population

observed: SGLT2 inhibitors Group in Adults with type 2 diabetes

variableDefinition

description:

Body weight

\n

variableRole: Outcome

observed: Body weight

Statistics

-DescriptionStatisticTypeQuantity
*

MEAN 86.08 Kg

\n
mean86.08 Kg
" }, "url" : "https://fevir.net/resources/Evidence/293991", "identifier" : [{ "type" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/v2-0203", "code" : "ACSN", "display" : "Accession ID" }], "text" : "FEvIR Object Identifier" }, "system" : "https://fevir.net/FOI", "value" : "293991", "assigner" : { "display" : "Computable Publishing LLC" } }, { "type" : { "text" : "outcomeId" }, "system" : "https://app.magicapp.org/#/guidelines", "value" : "109588" }, { "type" : { "text" : "picoId" }, "system" : "https://app.magicapp.org/#/guidelines", "value" : "85798" }, { "type" : { "text" : "sectionId" }, "system" : "https://app.magicapp.org/#/guidelines", "value" : "73215" }], "name" : "Body_weight_Intervention_Evidence_from_MAGICapp_109588", "title" : "MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes", "citeAs" : "MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293991. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293991. Computable resource at: https://fevir.net/resources/Evidence/293991#json.", "status" : "active", "author" : [{ "name" : "Computable Publishing®: MAGIC-to-FEvIR Converter" }], "publisher" : "Computable Publishing LLC", "contact" : [{ "telecom" : [{ "system" : "email", "value" : "support@computablepublishing.com" }] }], "useContext" : [{ "code" : { "system" : "https://fevir.net/resources/CodeSystem/179423", "code" : "evidence-communication", "display" : "Evidence Communication" }, "valueCodeableConcept" : { "coding" : [{ "system" : "https://fevir.net/resources/CodeSystem/179423", "code" : "InterventionOnlyEvidence", "display" : "InterventionOnlyEvidence" }] } }], "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/", "relatesTo" : [{ "type" : "part-of", "targetReference" : { "type" : "Composition", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "MAGIC-5288-j1Wqrn-conversion-report", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes" } }], "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.", "variableDefinition" : [{ "description" : "Adults with type 2 diabetes -- SGLT2 inhibitors", "variableRole" : "population", "observed" : { "reference" : "Group/236949", "type" : "Group", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "SGLT2 inhibitors Group in Adults with type 2 diabetes" } }, { "description" : "Body weight", "variableRole" : "outcome", "observed" : { "reference" : "EvidenceVariable/236986", "type" : "EvidenceVariable", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "MAGIC-5288-j1Wqrn-109588", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "Body weight" } }], "statistic" : [{ "description" : "MEAN 86.08 Kg", "statisticType" : { "coding" : [{ "system" : "https://fevir.net/sevco", "code" : "STATO:0000573", "display" : "mean" }] }, "quantity" : { "value" : 86.08, "unit" : "Kg" } }] }